Hybrid 4‐Aminoquinoline‐1, 3, 5‐triazine Derivatives: Design, Synthesis, Characterization, and Antibacterial Evaluation. (20th June 2014)

• Record Type: Journal Article
• Authors: Pathak, P.; Thakur, A.; Bhat, H. R.; Singh, U. P.
• Is Part Of: Journal of heterocyclic chemistry. Volume 52:Number 4(2015)
• Page Start: 1108
• Page End: 1113
• Publication Date: 2014-06-20
• Subjects: Heterocyclic compounds -- Periodicals; 547.59
• DOI: 10.1002/jhet.2210
• Languages: English
• ISSNs: 0022-152X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>A series of novel 4‐aminoquinoline 1, 3, 5‐triazine derivatives were synthesized and characterized by FTIR, ¹H‐NMR, ¹³C‐NMR, MS, and elemental analysis. The antibacterial activities of synthesized compounds were tested against three Gram‐positive bacteria, namely <italic>Bacillus subtilis</italic> (NCIM‐2063), <italic>Bacillus cereus</italic> (NCIM‐2156), and <italic>Staphylococcus aureus</italic> (NCIM‐2079), and four Gram‐negative bacteria, namely <italic>Proteus vulgaris</italic> (NCIM‐2027), <italic>Proteus mirabilis</italic> (NCIM‐2241), <italic>Escherichia coli</italic> (NCIM‐2065), and <italic>Pseudomonas aeruginosa</italic> (NCIM‐2036), using ciprofloxacin as reference standard drug. Results showed compound <bold>9a</bold> and <bold>9e</bold> as potent <named-content content-type="chemicalTechnology" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">antibacterial agents</named-content> against all bacterial strains except <italic>Bacillus cereus</italic> (NCIM‐2156). Copyright © 2014 HeteroCorporation</p> </abstract>